The use of Cox-2 and PPARγ signaling in anti-cancer therapies (Review)

Experimental and Therapeutic Medicine

Volumn 1, Issue 2, 2010, Pages 257-264

  Knopfová, Lucia ^a   Šmarda, Jan ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Cyclooxygenase 2; Nonsteroidal anti inflammatory drugs; Peroxisome proliferator activated receptor ; Prostaglandins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; CELECOXIB; CIGLITAZONE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUFENAMIC ACID; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIRINIXIC ACID; PROSTAGLANDIN F2 ALPHA; ROSIGLITAZONE; SULINDAC SULFIDE; TILMACOXIB; TROGLITAZONE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PREVENTION; CANCER THERAPY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; NONHUMAN; REGULATORY MECHANISM; REVIEW; UPREGULATION;

EID: 77956208412     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000040     Document Type: Review

References (93)

1. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1-20, 2004.
2. Liao Z, Mason KA and Milas L: Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 67: 821-845, 2007.
3. Koehne CH and Dubois RN: COX-2 inhibition and colorectal cancer. Semin Oncol 31: 12-21, 2004.
4. Khuder SA and Mutgi AB: Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84: 1188-1192, 2001.
5. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369, 2000.
6. Sooriakumaran P, Langley SE, Laing RW and Coley HM: COX-2 inhibition: a possible role in the management of prostate cancer? J Chemother 19: 21-32, 2007.
7. Muscat JE, Chen SQ, Richie JP Jr, Altorki NK, Citron M, Olson S, Neugut AI and Stellman SD: Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer 97: 1732-1736, 2003.
8. Sandler AB and Dubinett SM: COX-2 inhibition and lung cancer. Semin Oncol 31: 45-52, 2004.
9. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
10. Suzuki R, Yamamoto M, Saka H, Taniguchi H, Shindoh J, Tanikawa Y, Nomura F, Gonda H, Imaizumi K, Hasegawa Y and Shimokata K: A phase II study of carboplatin and paclitacel with meloxicam. Lung Cancer 63: 72-76, 2009.
11. Soriano F, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr and Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res 59: 6178-6184, 1999.
12. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R and Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131: 31-40, 2005.
13. Tachimori A, Yamada N, Amano R, Ohira M and Hirakawa K: Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28: 629-638, 2008.
14. Eichele K, Ramer R and Hinz B: Decisive role of cyclooxygenase-2 and lipocalin-type prostaglandin D synthase in chemotherapeutic-induced apoptosis of human cervical carcinoma cells. Oncogene 27: 3032-3044, 2008.
15. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ and Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5: 698-701, 1999.
16. Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645-650, 1990.
17. Nosjean O and Boutin JA: Natural ligands of PPARγ: Are prostaglandin J2 derivatives really playing the part? Cell Signal 14: 573-583, 2002.
18. Bull AW, Steffensen KR, Leers J and Rafter JJ: Activation of PPAR gamma in colon tumor cell lines by oxidized metabolites of linoleic acid, endogenous ligands for PPAR gamma. Carcinogenesis 24: 1717-1722, 2003.
19. Kepez A, Oto A and Dagdelen S: Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance and atherosclerosis. BioDrugs 20: 121-135, 2006.
20. Chiarelli F and Di Marzio D: Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc Health Risk Manag 4: 297-304, 2008.
21. Quinn CE, Hamilton PK, Lockhart CJ and McVeigh GE: Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 153: 636-645, 2008.
22. Konstantinopoulos PA, Vandoros GP, Sotiropoulou-Bonikou G, Kominea A and Papavassiliou AG: NF-κB/PPARγ and/or AP-1/PPAR PPAR γ 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int J Colorectal Dis 22: 57-68, 2007.
23. Badawi AF and Badr MZ: Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 103: 84-90, 2003.
24. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K and Kohri K: Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev 32: 259-266, 2008.
25. Matsuyama M and Yoshimura R: Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res 2008: 249849, 2008.
26. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, Kishimoto T and Sano H: Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51: 108-116, 2002.
27. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N and Kinoshita Y: Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 83: 1394-1400, 2000.
28. Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T and Sano H: Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res 21: 2471-2476, 2001.
29. Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M and Pilarsky C: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res 12: 6444-6451, 2006.
30. Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM and Catapano CV: Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861, 2006.
31. Jung TI, Baek WK, Suh SI, Jang BC, Song DK, Bae JH, Kwon KY, Bae JH, Cha SD, Bae I and Cho CH: Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol 97: 365-373, 2005.
32. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5: 419-429, 2004.
33. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP and Standiford TJ: Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23: 100-108, 2004.
34. Yasui Y, Kim M and Tanaka T: PPAR ligands for cancer chemoprevention. PPAR Res 2008: 548919, 2008.
35. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM and Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97: 10990-10995, 2000.
36. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y and Kinoshita Y: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4: 465-477, 2004.
37. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R and Auwerx J: Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4: 1053-1057, 1998.
38. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA and Evans RM: Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4: 1058-1061, 1998.
39. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC and Evans RM: PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18: 528-540, 2004.
40. Eibl G: The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res 2008: 326915, 2008.
41. Kawashima A, Harada T, Imada K, Yano T and Mizuguchi K: Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Prostaglandins Leukot Essent Fatty Acids 79: 59-65, 2008.
42. Allred CD, Talbert DR, Southard RC, Wang X and Kilgore MW: PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. J Nutr 138: 250-256, 2008.
43. Straus DS and Glass CK: Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21: 185-210, 2001.
44. Matsuoka T and Narumiya S: Prostaglandin receptor signaling in disease. ScientificWorldJournal 7: 1329-1347, 2007.
45. Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310: 1504-1510, 2005.
46. Chan TA: Prostaglandins and the colon cancer connection. Trends Mol Med 12: 240-244, 2006.
47. Scher JU and Pillinger MH: 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol 114: 100-109, 2005.
48. Shimada T, Kojima K, Yoshiura K, Hiraishi H and Terano A: Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand-induced apoptosis in colon cancer cells. Gut 50: 658-664, 2002.
49. Millan O, Rico D, Peinado H, Zarich N, Stamatakis K, Pérez-Sala D, Rojas JM, Cano A and Boscá L: Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis. Carcinogenesis 27: 328-336, 2006.
50. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, Oates JA and Morrow JD: Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 59: 2739-2746, 1999.
51. Reginato MJ, Krakow SL, Bailey ST and Lazar MA: Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. J Biol Chem 273: 1855-1858, 1998.
52. Padilla J, Kaur K, Cao HJ, Smith TJ and Phipps RP: Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol 165: 6941-6948, 2000.
53. Jaradat MS, Wongsud B, Phornchirasilp S, Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ and Feller DR: Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen and indomethacin. Biochem Pharmacol 62: 1587-1595, 2001.
54. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410, 1997.
55. López-Parra M, Clària J, Titos E, Planagumà A, Párrizas M, Masferrer JL, Jiménez W, Arroyo V, Rivera F and Rodés J: The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin. J Hepatol 42: 75-81, 2005.
56. Diamond MP and Saed G: Modulation of the expression of peroxisome proliferator-activated receptors in human fibroblasts. Fertil Steril 87: 706-709, 2007.
57. Shaik MS, Chatterjee A and Singh M: Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res 10: 1521-1529, 2004.
58. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S and Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther 302: 18-25, 2002.
59. Cui W, Yu CH and Hu KQ: In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 11: 8213-8221, 2005.
60. Nagahara T, Okano J and Murawaki Y: Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol Rep 18: 1281-1290, 2007.
61. Meade EA, McIntyre TM, Zimmerman GA and Prescott SM: Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 274: 8328-8334, 1999.
62. Pontsler AV, St Hilaire A, Marathe GK, Zimmerman GA and McIntyre TM: Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem 277: 13029-13036, 2002.
63. Bishop-Bailey D and Warner TD: PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist. FASEB J 17: 1925-1927, 2003.
64. Kalajdzic T, Faour WH, He QW, Fahmi H, Martel-Pelletier J, Pelletier JP and Di Battista JA: Nimesulide, a preferential cyclooxygenase 2 inhibitor, suppresses peroxisome proliferator-activated receptor induction of cyclooxygenase 2 gene expression in human synovial fibroblasts: evidence for receptor antagonism. Arthritis Rheum 46: 494-506, 2002.
65. Lee JH, Yu SM, Yoon EK, Lee WK, Jung JC and Kim SJ: 15-Deoxy-delta 12,14-prostaglandin J2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes. J Korean Med Sci 22: 891-897, 2007.
66. Patel KM, Wright KL, Whittaker P, Chakravarty P, Watson ML and Ward SG: Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma). Cell Signal 17: 1098-1110, 2005.
67. Chêne G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M and Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta 1771: 576-589, 2007.
68. Pang L, Nie M, Corbett L and Knox AJ: Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J Immunol 170: 1043-1051, 2003.
69. Ulivi V, Cancedda R and Cancedda FD: 15-Deoxy-delta 12,14-prostaglandin J(2) inhibits the synthesis of the acute phase protein SIP24 in cartilage: involvement of COX-2 in resolution of inflammation. J Cell Physiol 217: 433-441, 2008.
70. Li Z, Jansen M, Ogburn K, Salvatierra L, Hunter L, Mathew S and Figueiredo-Pereira ME: Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish? J Neurosci Res 78: 824-836, 2004.
71. Ulivi V, Giannoni P, Gentili C, Cancedda R and Descalzi F: p38/NF -κB-dependent expression of COX-2 during differentiation and inflammatory response of chondrocytes. J Cell Biochem 104: 1393-1406, 2008.
72. Tsatsanis C, Androulidaki A, Venihaki M and Margioris AN: Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38: 1654-1661, 2006.
73. Paik JH, Ju JH, Lee JY, Boudreau MD and Hwang DH: Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. J Biol Chem 275: 28173-28179, 2000.
74. Boyault S, Simonin MA, Bianchi A, Compe E, Liagre B, Mainard D, Becuwe P, Dauca M, Netter P, Terlain B and Bordji K: 15-Deoxy-Δ12;14-PGJ2, but not troglitazone, modulates IL-1β effects in human chondrocytes by inhibiting NF-κB and AP-1 activation pathways. FEBS Lett 501: 24-30, 2001.
75. Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, He Y and Huang RW: Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol 86: 173-183, 2007.
76. Hazra S and Dubinett SM: Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostaglandins Leukot Essent Fatty Acids 77: 51-58, 2007.
77. Bren-Mattison Y, Meyer AM, van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE and Nemenoff RA: Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73: 709-717, 2008.
78. Delerive P, Gervois P, Fruchart JC and Staels B: Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem 275: 36703-36707, 2000.
79. Moraes LA, Piqueras L and Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110: 371-385, 2006.
80. Wahli W: A gut feeling of the PXR, PPAR and NF-κB connection. J Intern Med 263: 613-619, 2008.
81. Ricote M, Li AC, Willson TM, Kelly CJ and Glass CK: The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391: 79-82, 1998.
82. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M and Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103-108, 2000.
83. Ackerman WE, Zhang XL, Rovin BH and Kniss DA: Modulation of cytokine-induced cyclooxygenase 2 expression by PPARG ligands through NFκB signal disruption in human WISH and amnion cells. Biol Reprod 73: 527-535, 2005.
84. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G and Glass CK: 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 97: 4844-4849, 2000.
85. Badawi AF and Badr MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-γ. Int J Oncol 20: 1109-1122, 2002.
86. Michael MS, Badr MZ and Badawi AF: Inhibition of cyclo-oxygenase-2 and activation of peroxisome proliferator-activated receptor-γ synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 11: 733-736, 2003.
87. Badawi AF, Eldeen MB, Liu Y, Ross EA and Badr MZ: Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 64: 1181-1189, 2004.
88. Mustafa A and Kruger WD: Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clin Cancer Res 14: 4935-4942, 2008.
89. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS and Ding GX: Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255, 2009.
90. Narayanan NK, Narayanan BA and Reddy BS: A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-κB, and steroid hormone receptors. Int J Oncol 26: 785-792, 2005.
91. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lönnroth C and Lundholm K: EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121: 232-240, 2007.
92. Hazra S, Peebles KA, Sharma S, Mao JT and Dubinett SM: The role of PPARgamma in the cyclooxygenase pathway in lung cancer. PPAR Res 2008: 790568, 2008.
93. Sasaki H, Tanahashi M, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y and Fujii Y: Decreased peroxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. Lung Cancer 36: 71-76, 2002.